• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Define Ventures Appoints Bruce Broussard as Venture Partner

    10/22/24 9:00:00 AM ET
    $EVH
    $HIMS
    $HUM
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care
    Get the next $EVH alert in real time by email

    The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation

    SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companies. 

    Bruce is a seasoned healthcare executive and multi-time CEO, having held executive leadership positions across multiple corners of the ecosystem. Prior to joining Define, Bruce was president and CEO of Humana for over a dozen years. Under his leadership, Bruce led a strategic shift towards expanding the company into an integrated model with a growing care delivery focus. Bruce also held several roles at McKesson Specialty Health including CEO, CFO, President, and Chairman of the Board. He currently serves on the Humana Foundation Board, is Chair of the Board of Directors of the Trust for the National Mall, and is a board member for HP Inc. and One Call.

    "Bruce's extensive background and proven track record in leading healthcare organizations of all sizes makes him uniquely qualified to guide the next generation of health tech innovators," said Lynne Chou O'Keefe, founder and managing partner at Define Ventures. "Having had the privilege to closely partner with Bruce for the past decade, I am confident his decision to join our team will sharpen our investing theses, accelerate our partner companies' growth, strengthen our relationships with large healthcare organizations, and ultimately create a lasting impact on the broader health tech community."

    Bruce is joining a team that pulls the full weight of its network and expertise to play offense and drive results, including securing early customers, shaping commercial strategies, and building high-performing teams. As venture partner, Bruce will leverage his experience driving transformative change within complex healthcare organizations to help Define founders to navigate industry challenges and scale their innovations effectively. His perspective will also strengthen Define's close partnerships with its coalition of large health systems, health plans, employers, and life sciences companies, half of which are customers of Define partner companies.

    "What excites me the most about this role is the opportunity to work with brilliant, innovative entrepreneurs at the earliest stages of their journey," Broussard said. "Being able to see groundbreaking approaches from the start, and having the chance to shape products and help scale and bring them to market is truly invigorating. Ultimately, I chose to work with Define because I believe this firm is uniquely positioned and capable of driving real transformation in healthcare. The strong, trustworthy relationship we've built over the years has shown me that Define's vision aligns perfectly with my own. Together, I believe we can make significant strides in creating a healthcare system that's more efficient, more accessible, and more focused on keeping people healthy."

    Bruce's decision to join Define Ventures stems from his belief that the firm is uniquely positioned and capable of transforming healthcare. He has built a strong and trustworthy relationship with Define over the past several years, including first-hand experience in incubating and spinning out Cohere Health from Humana. This collaborative history underscores the alignment between Bruce's vision for healthcare innovation and Define's strategic approach.

    Define Ventures has $800 million in assets under management and partners with companies at the seed, series A and series B stages. The firm attracts leading health tech entrepreneurs with its high conviction approach, partnering with over two dozen companies including Hims & Hers (NYSE:HIMS) and Unite Us. This announcement follows Frank Williams, co-founder and former CEO of Evolent (NYSE:EVH) joining Define as venture partner earlier this year.

    To learn more about Define Ventures, visit www.definevc.com.

    About Define Ventures

    Define Ventures is one of the largest funds focused on early-stage health tech companies. With $800 AUM, we take a high conviction approach in partnering with companies at the earliest stages. We believe the future of healthcare will be defined who bring together a deep understanding of the healthcare ecosystem paired with a technology-driven mindset. Our team was built in this vision, bringing together founders and investors who built category-defining companies and delivered $23 billion in exit value, including Livongo (LVGO), Evolent (NYSE:EVH), and Hims & Hers (NYSE:HIMS).

    Cision View original content:https://www.prnewswire.com/news-releases/define-ventures-appoints-bruce-broussard-as-venture-partner-302282546.html

    SOURCE Define Ventures

    Get the next $EVH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who has joined Define Ventures as a venture partner, and what is his background?

      Bruce Broussard, the former CEO of Humana, has joined Define Ventures as a venture partner to drive transformative change in healthcare and support early-stage health tech companies.

    • What is Define Ventures' focus and how much capital do they manage?

      Define Ventures focuses on early-stage health tech companies and has $800 million in assets under management (AUM). They partner with companies typically at the seed, series A, and series B stages.

    • Why has Bruce Broussard chosen to work with Define Ventures?

      Broussard believes Define Ventures is uniquely positioned to drive real transformation in healthcare, based on his strong relationship with the firm and shared vision for healthcare innovation.

    • What role will Bruce Broussard play at Define Ventures?

      Broussard will leverage his extensive experience in healthcare to guide founders through challenges, helping them scale their innovations and strengthen partnerships with large healthcare organizations.

    • Which companies has Define Ventures partnered with, showcasing their investment strategy?

      Define Ventures has partnered with notable companies in the health tech space, including Hims & Hers and Unite Us, highlighting their investment strategy focused on impactful entrepreneurs.

    Recent Analyst Ratings for
    $EVH
    $HIMS
    $HUM

    CompanyDatePrice TargetRatingAnalyst
    Humana Inc.
    $HUM
    5/20/2026$441.00Hold → Buy
    Deutsche Bank
    Hims & Hers Health Inc.
    $HIMS
    5/12/2026$30.00 → $35.00Buy
    Needham
    Hims & Hers Health Inc.
    $HIMS
    4/24/2026$35.00Overweight
    Analyst
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Evolent Health Inc
    $EVH
    2/25/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Hims & Hers Health Inc.
    $HIMS
    2/24/2026Buy → Neutral
    BTIG Research
    More analyst ratings

    $EVH
    $HIMS
    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims

    An expert in longevity medicine and preventive healthcare, Vinjamoori joins Hims & Hers to help more men feel great at every stage of life Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced Dr. Anant Vinjamoori is joining as the Chief Medical Officer of the Hims brand. As the company reimagines how everyone can access proactive, comprehensive care that helps them feel great, Dr. Vinjamoori will provide the clinical guidance that shapes the next phase of the Hims brand across sexual health, hormone health, dermatology, weight loss, and mental health, as well as emerging categories like longevity medicine and peptide therapy. He joins a team of m

    6/4/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians

    Building on its Canadian launch and the historic introduction of generic semaglutide, Hims & Hers brings the full power of the world's largest consumer health platform — and Juniper's proven track record — to more Canadians than ever Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company investments in Canada. Since launching in 2025, Hims & Hers has already changed the game in Canada, becoming the first platform to bring generic semaglutide to eligible Canadians. By combining Juniper's proven platform with the technology, data, and clinical infrastructure that has advan

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform

    The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people Hims & Hers Health, Inc. (NYSE:HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on the earlier acquisitions of ZAVA and Livewell, Hims & Hers now has a leading presence across the US, UK, Australian, and Canadian markets, with a growing presence in France, Germany, Ireland, Spain, and Japan. Continuing to expand internationally will enable Hims & Hers to lead the next era of digital health, delivering personal, af

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    SEC Filings

    View All

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    6/2/26 6:02:26 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - HUMANA INC (0000049071) (Filer)

    6/1/26 6:37:55 AM ET
    $HUM
    Medical Specialities
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    5/21/26 5:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wells David B bought $1,172,974 worth of shares (48,400 units at $24.23), increasing direct ownership by 27% to 224,417 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/26/26 4:48:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HIMS
    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Humana upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Humana from Hold to Buy and set a new price target of $441.00

    5/20/26 8:04:21 AM ET
    $HUM
    Medical Specialities
    Health Care

    Needham reiterated coverage on Hims & Hers Health with a new price target

    Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $35.00 from $30.00 previously

    5/12/26 10:08:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Analyst initiated coverage on Hims & Hers Health with a new price target

    Analyst initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $35.00

    4/24/26 8:05:39 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wells David B bought $1,172,974 worth of shares (48,400 units at $24.23), increasing direct ownership by 27% to 224,417 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/26/26 4:48:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Medical Officer Carroll Patrick Harrison

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/26 4:16:21 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Director Wells David B

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/26 4:16:05 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Leadership Updates

    Live Leadership Updates

    View All

    Humana, CenterWell and USAA Unite with VFW for National Day of Service Supporting Veterans Experiencing Homelessness

    Collaborative service projects in Tampa, San Antonio and Nashville highlight shared commitment to veterans' health, dignity and well-being Humana Inc. and the Veterans of Foreign Wars (VFW), in collaboration with CenterWell, USAA and Volunteers of America (VOA), will bring together employees, veteran advocates and community partners on May 19 to support veterans experiencing homelessness. As part of the VFW's annual Day of Service, volunteers will unite in three different locations — Nashville, Tennessee; San Antonio, Texas; and Tampa, Florida — for hands-on service projects that deliver tangible support to veterans and seniors in need. Collectively, volunteers at the three locations wi

    5/14/26 8:23:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Quest Analytics Expands Leadership Team with Appointment of Chris Lance as Chief Product Officer

    Accomplished product leader to drive innovation, platform strategy, and AI-powered solutions for health plan clientsOVERLAND PARK, Kan., May 12, 2026 /PRNewswire/ -- Quest Analytics® today announced the appointment of Chris Lance as Chief Product Officer (CPO). In this role, Lance will lead vision, strategy, and execution across the company's full product portfolio, driving innovation that helps health plans build, manage, model, and optimize high-performing provider networks. Lance brings more than 20 years of experience leading product and technology organizations, with a prov

    5/12/26 7:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

    If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company's 2026 annual shareholder meeting in June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428343333/en/If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise. Amoo-Gottfried is a seasoned marketing l

    4/28/26 8:35:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results

    Revenue of approximately $608 million, up 4% year-over-year in Q1 2026 Subscribers grew to nearly 2.6 million, up 9% year-over-year in Q1 2026 Raises full year 2026 revenue guidance1 to a range of $2.8 billion to $3.0 billion and updates Adjusted EBITDA guidance to a range of $275 million to $350 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2026. Moving forward, the Company plans to transition to an annual rather than quarterly shareholder letter and will continue to provide regular updates through a quarterly earnings call, earnings rele

    5/11/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Evolent Announces First Quarter 2026 Results

    WASHINGTON, May 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2026.Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "I am happy with the strong start to the year. We are on track with our plan and have had successful, on-time oncology launches at both Highmark and Aetna. As we look into 2027 and beyond, we remain focused on both extending our market leadership in oncology and addressing the big opp

    5/7/26 7:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Humana Reports First Quarter 2026 Financial Results; Affirms Full Year 2026 Adjusted Financial Guidance

    Reports 1Q26 earnings per share (EPS) of $9.83 on a GAAP basis, Adjusted EPS of $10.31; at the high end of the company's guidance of approximately 110 percent to 115 percent of full year (FY) 2026 Adjusted EPS 1Q26 Insurance segment GAAP benefit ratio of 89.4 percent, slightly favorable to management's guidance of 'just under 90 percent'; affirms FY 2026 Insurance segment benefit ratio guidance of 92.75 percent, plus or minus 25 basis points Affirms Adjusted FY 2026 GAAP EPS guidance of 'at least $9.00'; while revising GAAP EPS guidance to 'at least $8.36' from the previous estimate of 'at least $8.89' Affirms FY 2026 individual Medicare Advantage (MA) membership growth of 'approx

    4/29/26 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care